期刊
KIDNEY INTERNATIONAL
卷 91, 期 3, 页码 658-670出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.09.041
关键词
ABCG2; chronic kidney disease; parathyroid hormone; secondary hyperparathyroidism; urate
资金
- Japan Society for the Promotion of Science [KAKENHI 23790187, 25460190, 25460652, 16H05114]
- Research Foundation for Pharmaceutical Sciences, Japan
- Kidney Foundation, Japan
- Grants-in-Aid for Scientific Research [25460190, 16H05114, 16K15320, 25460652] Funding Source: KAKEN
Hyperuricemia occurs with increasing frequency among patients with hyperparathyroidism. However, the molecular mechanism by which the serum parathyroid hormone (PTH) affects serum urate levels remains unknown. This was studied in uremic rats with secondary hyperparathyroidism where serum urate levels were found to be increased and urate excretion in the intestine and kidney decreased, presumably due to down-regulation of the expression of the urate exporter ABCG2 in intestinal and renal epithelial membranes. These effects were prevented by administration of the calcimimetic cinacalcet, a PTH suppressor, suggesting that PTH may down-regulate ABCG2 expression. This was directly tested in intestinal Caco-2 cells where the expression of ABCG2 on the plasma membrane was down-regulated by PTH (1-34) while its mRNA level remained unchanged. Interestingly, an inactive PTH derivative (13-34) had no effect, suggesting that a posttranscriptional regulatory system acts through the PTH receptor to regulate ABCG2 plasma membrane expression. As found in an animal study, additional clinical investigations showed that treatment with cinacalcet resulted in significant reductions in serum urate levels together with decreases in PTH levels in patients with secondary hyperparathyroidism undergoing dialysis. Thus, PTH down-regulates ABCG2 expression on the plasma membrane to suppress intestinal and renal urate excretion, and the effects of PTH can be prevented by cinacalcet treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据